

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-31) VOLAGIDEMAB

PRONUNCIATION vol" a jid' e mab

THERAPEUTIC CLAIM Treatment of type 1 and type 2 diabetes, defects of insulin function or insulin receptor signaling, iatrogenic hyperglycemia

CHEMICAL NAMES

1. Immunoglobulin G2, anti-(human glucagon receptor) (human monoclonal REMD 477 γ 2-chain), disulfide with human monoclonal REMD 477 κ -chain, dimer
2. immunoglobulin G2-kappa, anti-(*Homo sapiens* glucagon receptor); *Homo sapiens* monoclonal antibody; γ 2 heavy chain (1-454) [*Homo sapiens* VH (IGHV3-33*01 (96%) –(IGHD)-IGHJ1*01 (91%)) [8.8.21] (1-128) -*Homo sapiens* IGHG2*01 (129-454)] (142-214')-disulfide with κ light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (97%) –IGKJ4*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (230-230":231-231":234-234":237-237")-tetrakisdisulfide

STRUCTURAL FORMULA

Heavy chain

QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	SYGMHWVRQA	PGKGLEWVAV	50
MWYDGSNKDY	VDSVKGRFTI	SRDNSKNTLY	LQMNRLRAED	TAVYYCAREK	100
DHYDILTGYN	YYYGLDVWQG	GTTVTVSSAS	TKGPSVFPLA	PCSRSTSEST	150
AALGCLVKDY	FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	200
SSNFGTQTYT	CNVDHKPSNT	KVDKTVERKC	CVECPPCPAP	PVAGPSVPLF	250
PPKPKDTLMI	SRTPEVTCVV	VDVSHEDPEV	QFNWYVDGVE	VHNAKTKPRE	300
EQFNTSFRVV	SVLTVVHQDW	LNGKEYKCKV	SNKGLPAPIE	KTISKTKGQP	350
REPQVYTLPP	SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	400
TPPMLDSDGS	FFLYSKLTVD	KSRWQQGNVF	SCSVMHEALH	NHYTQKSLSL	450
SPGK					454

Light chain

DIQMTQSPSS	LSASVGDRTV	ITCRASQGIR	NDLGWYQQKP	GKAPKRLIYA	50'
ASSLQSGVPS	RFSGSGSGTE	FLLTISSVQP	EDFVTTYCLQ	HNSNPLTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-96	22"-96"	23'-88'	23"-88"	134'-194'	134"-194"
142-214'	142"-214"	155-211	155"-211"	230-230"	231-231"
234-234"	237-237"	268-328	268"-328"	374-432	374"-432"

Glycosylation sites (N)

Asn-304 Asn-304"

MOLECULAR FORMULA $C_{6502}H_{10034}N_{1758}O_{2032}S_{52}$ (non-glycosylated)

MOLECULAR WEIGHT 147.0 kDa (non-glycosylated)

TRADEMARK	None as yet
SPONSOR	REMD Biotherapeutics Inc.
CODE DESIGNATIONS	REMD-477, AMG 477
<u>CAS</u> REGISTRY NUMBER	1233956-13-2
UNII	77JYS6UZ0M
WHO NUMBER	10989

gbk